COX-1/PGE2/EP4 alleviates mucosal injury by upregulating β-arr1-mediated Akt signaling in colitis

Xiaojie Peng1, Jianzhong Li1, Siwei Tan1

  • 1Department of Gastroenterology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.

Scientific Reports
|April 23, 2017
PubMed

Insights

Cyclooxygenase-1 (COX-1) and prostaglandin E2 (PGE2) protect the gut lining in ulcerative colitis (UC). This study reveals that PGE2 enhances beta-arrestin1 (β-arr1) to activate the Akt pathway, promoting mucosal healing in colitis.

Area of Science:

  • Gastroenterology and Immunology
  • Molecular and Cellular Biology

Background:

  • Ulcerative colitis (UC) involves impaired mucosal barrier function.
  • Cyclooxygenase-1 (COX-1) and prostaglandin E2 (PGE2) are recognized protective mediators in UC.
  • The role of β-arrestin1 (β-arr1) in PGE2-mediated signaling and mucosal integrity is not fully understood.

Purpose of the Study:

  • To investigate the interaction between PGE2 and β-arr1 in maintaining mucosal barrier integrity during colitis.
  • To elucidate the signaling pathway involved in PGE2-mediated mucosal protection.

Main Methods:

  • Analysis of COX-1, PGE2, and EP4 expression in UC patients and dextran sulfate sodium (DSS)-induced colitis mouse models.
  • Assessment of colitis severity and signaling pathway activation (PI3K/Akt) in wild-type (WT) and β-arr1 deficient mice.
  • In vitro studies using HCT116 cells with β-arr1 siRNA to evaluate the effect of PGE2 on β-arr1 expression and signaling.

Main Results:

  • COX-1, PGE2, and EP4 were downregulated in UC patients and DSS-induced colitis mice.
  • PGE2 treatment alleviated mucosal injury and upregulated EP4 in WT mice.
  • β-arr1 deficiency exacerbated colitis and downregulated PI3K/Akt signaling.
  • PGE2 treatment upregulated β-arr1 expression in vivo and in vitro.

Conclusions:

  • The COX-1/PGE2/EP4 pathway upregulates β-arr1, which mediates Akt signaling to protect the colonic mucosa.
  • This pathway is crucial for maintaining mucosal barrier integrity during colitis.
  • Targeting the COX-1/PGE2 pathway holds potential for UC treatment.

Related Concept Videos

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.4K
Pathophysiology of Peptic Ulcer Disease: Injurious Factors01:22

Pathophysiology of Peptic Ulcer Disease: Injurious Factors

Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
1.4K
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
1.4K
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
1.5K
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
7.9K
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.8K